1. Introduction {#sec1}
===============

Liver cirrhosis is the 13th major cause of death worldwide. Acute upper gastrointestinal bleeding (AUGIB) is a frequent medical emergency with a high incidence of 45-172/100,000 each year in the general population and is a lethal complication of liver cirrhosis leading to an in-hospital mortality of 10% \[[@B1], [@B2]\]. Due to the acute performance of AUGIB itself, early diagnosis and timely management are needed. Notably, there are general shortage of staff, a potentially lower professional level of staff, and delayed use of endoscopy during weekends and holidays, which may lead to worse outcomes \[[@B3], [@B4]\]. Previous studies evaluated the effect of admission time on the outcomes of patients with AUGIB, but their findings were inconsistent. Some authors supported the "weekend effect" that patients admitted during weekends had worse outcomes \[[@B5]--[@B9]\], such as higher mortality and rebleeding rate, longer length of stay, and increased cost. On the contrary, others suggested no significant difference in the mortality between patients admitted during weekends and weekdays \[[@B10]--[@B15]\]. A meta-analysis \[[@B16]\] reported that off-hours admission was significantly associated with an increased mortality and less timely endoscopy in patients with nonvariceal bleeding but not those with variceal bleeding. More recently, another meta-analysis \[[@B17]\] also had similar results. However, there were some limitations in previous studies.

First, meta-analyses have shown that geographical variation leads to different weekend effect on outcomes \[[@B16], [@B17]\]. A study, which included 571 patients suspected with upper gastrointestinal bleeding (UGIB) from 8 participating hospitals in the Netherlands \[[@B11]\], reported that patients admitted on weekends had higher mortality and rebleeding rate than those admitted on weekdays. By contrast, two prospective studies \[[@B14], [@B15]\] conducted in the United Kingdom found no significant difference in mortality of patients with UGIB between weekend and weekday admission groups. A retrospective study conducted in Korea \[[@B12]\], which included 294 cirrhotic patients with acute variceal bleeding, found no significant difference in the in-hospital mortality between weekend and weekday admission groups. Notably, all studies included in the two meta-analyses were not conducted in China mainland. Considering a geographical difference in the staff schedule and management and outcome of AUGIB, further studies should be performed in China mainland.

Second, meta-analyses have also shown that a variation in the source of bleeding leads to different weekend effect on outcomes. All of 4 studies conducted in the United States were based on Nationwide Inpatient Sample, but showed different results \[[@B5], [@B6], [@B8], [@B13]\]. The first study demonstrated that patients with UGIB regardless of source of bleeding admitted on weekends had significantly higher mortality and longer length of stay than those admitted on weekdays \[[@B5]\]. The second study also demonstrated that patients with peptic ulcer hemorrhage admitted on weekends had higher mortality and longer length of stay \[[@B6]\]. The third study further confirmed that patients with nonvariceal UGIB admitted on weekends had higher mortality \[[@B8]\]. However, the fourth study found that the mortality in patients with acute variceal bleeding was similar between weekend and weekday admission groups \[[@B13]\].

Third, previous studies usually compared the effect of weekends versus weekdays on the mortality of AUGIB. But the nighttime during weekdays was often ignored from the definition of off-hours. Thus, further studies should refine the interval of off-hours.

Herein, we performed a retrospective study to compare the outcomes of patients with liver cirrhosis and AUGIB who were admitted to a large tertiary hospital of Northeastern China on regular hours versus off-hours.

2. Methods {#sec2}
==========

2.1. Study Design {#sec2.1}
-----------------

We reviewed the medical records of cirrhotic patients who were consecutively admitted to the General Hospital of Shenyang Military Area from January 2010 to June 2014 as the test cohort. All patients with a diagnosis of liver cirrhosis and AUGIB were eligible. Additionally, we are prospectively collecting all cirrhotic patients who were admitted to our department and underwent contrast-enhanced CT scans and endoscopy since December 2014. Thus, based on the data during the patients\' enrollment and follow-up, a validation cohort of cirrhotic patients with AUGIB between December 2014 and March 2018 was established for the present study. Age and sex were not limited. The source of bleeding was not limited. Patients with liver and other malignancies were excluded. Patients with incomplete case information and unavailable electronic medical records were also excluded. Data from repeated admission was not deliberately excluded. The outcomes we observed included 5-day rebleeding rate, in-hospital mortality, length of hospital stay, and total payment during hospitalizations. This study was approved by the Medical Ethical Committee of our hospital and the ethical approval number was k (2017)42. The patient\'s informed consent was not required in the retrospective study.

2.2. Data Collection {#sec2.2}
--------------------

The primary data collected were age, sex, admission time, etiology of liver disease, and laboratory tests (i.e., red blood cell, hemoglobin, white blood cell, platelet count, total bilirubin, direct bilirubin, indirect bilirubin, albumin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, blood urea nitrogen, creatinine, potassium, sodium, prothrombin time, activated partial thromboplastin time, and international normalized ratio \[INR\]). The severity of esophageal varices was also collected. Treatment options of AUGIB were collected as follows: endoscopic therapy (i.e., band ligation, sclerotherapy, and histoacryl), Sengstaken Blackmore tube, somatostatin and/or octreotide, blood transfusion, proton pump inhibitors (PPIs), and surgery.

2.3. Definitions and Formulas {#sec2.3}
-----------------------------

AUGIB was defined as hematemesis and/or melena within 5 days before our admission or positive occult blood test at the day of admission \[[@B18]\]. Regular hours referred to the interval from 8:00 AM to 17:00 PM at the weekdays (i.e., from Monday to Friday). Otherwise, off-hours were considered, and weekends and public holidays were also considered as off-hours. Child-Pugh score \[[@B19]\] was calculated according to hepatic encephalopathy, ascites, total bilirubin, albumin, and INR. Model for end-stage liver disease (MELD) score=9.57 ×  ln⁡  (creatinine  \[*μ*mol/L\] × 0.01)  + 3.78 ×  ln⁡(bilirubin  \[*μ*mol/L\] × 0.05) + 11.2 ×  ln ⁡(INR)  + 0.643 \[[@B20]\]. According to the study by Reverter et al. \[[@B21]\], recalibrated MELD score=-5.312+0.207×MELD. Albumin-bilirubin (ALBI) score=-0.085 × albumin (g/L) + 0.66 ×  log~10~⁡bilirubin  (*μ*mol/L) \[[@B22], [@B23]\].

2.4. Statistical Analyses {#sec2.4}
-------------------------

Continuous variables were reported as median (range) and were compared using the nonparametric Mann-Whitney U test. Categorical variables were reported as frequency (percentage) and were compared using the chi-square test. Subgroup analyses were also conducted based on the presence of varices on endoscopy (AUGIB with endoscopically confirmed varices and without varices on endoscopy). A 1:1 propensity score matching analysis was performed to adjust the effect of gender, age, Child-Pugh score, MELD score, and recalibrated MELD score on the outcomes. A two-tailed P\<0.05 was considered statistically significant. All statistical analyses were performed with IBM SPSS 20.0 (IBM Corp.) statistical package and Stata/SE 12.0 (Stata Corp, College Station, TX) software.

3. Results {#sec3}
==========

3.1. Test Cohort {#sec3.1}
----------------

### 3.1.1. Patients\' Characteristics {#sec3.1.1}

Between January 2010 and June 2014, a total of 826 patients with liver cirrhosis and AUGIB were included. Baseline patient characteristics are described in [Table 1](#tab1){ref-type="table"}. Median age was 55.27 years (range: 6.28 to 95.13). Among them, 564 (68.3%) patients were male. Major etiology of liver diseases included hepatitis B virus infection (n=208, 25.2%) and alcohol abuse (n=219, 26.5%). A majority of patients had Child-Pugh class B (339/776, 51.4%). Median MELD score at admission was 6.37 (-7.52 to 38.22). Five hundred and twenty-two patients underwent endoscopy. No, mild, moderate, and severe esophageal varices were observed in 32 (6.1%), 24 (4.6%), 54 (10.3%), and 412 (78.9%) patients, respectively. As for the treatment of AUGIB, 508 (61.5%) patients underwent endoscopic therapy, 20 (2.4%) patients underwent Sengstaken Blackmore tube placement, 750 (90.8%) patients received somatostatin and/or octreotide, 544 (65.9%) patients received blood transfusion, 813 (98.4%) patients received PPIs, and 8 (1.0%) patients underwent surgery. Information regarding 5-day rebleeding was unavailable in 4 patients, because some of their medical records were missing. Five-day rebleeding rate was 14.0% (115/822). In-hospital mortality was 5.7% (47/826). Median length of hospital stay was 11.23 days (range: 0.06 to 100.55). Total payment was ¥23,120.87 (range: 1,287.54 to 226,872.93).

### 3.1.2. Outcome {#sec3.1.2}

Patients admitted on off-hours had lower serum albumin (P\<0.001) and higher white blood cell (P\<0.001), blood urea nitrogen (P\<0.001), potassium (P\<0.001), prothrombin time (P=0.034), INR (P=0.040), Child-Pugh score (P=0.006), and ALBI score (P\<0.001) than those admitted on regular hours ([Table 1](#tab1){ref-type="table"}). As for the interventions, patients admitted on off-hours had a higher proportion of blood transfusion than those admitted on regular hours (73.3% versus 60.7%, P\<0.001). Among the different departments of our hospital, there was no significant difference in the selection of most treatment options for AUGIB between patients admitted on regular hours and off-hours (Supplementary [Table 1](#supplementary-material-1){ref-type="supplementary-material"}). As for the outcomes, patients admitted on off-hours had a higher 5-day rebleeding rate (18.7% versus 10.7%, P=0.001) and a larger amount of payment (¥25,906.83 versus ¥22,017.42, P\<0.001). In-hospital mortality was not significantly different between the two groups (P=0.418). Length of stay was not significantly different between the two groups (P=0.830).

### 3.1.3. Subgroup Analyses {#sec3.1.3}

The origin of bleeding could be evaluated in 611 patients in the test cohort. They included 591 patients with endoscopically confirmed esophageal and/or gastric varices and 20 patients without varices at endoscopy (Supplementary [Table 2](#supplementary-material-1){ref-type="supplementary-material"}).

Among the patients with endoscopically confirmed varices, patients admitted on off-hours were older (P=0.015) and had lower red blood cell (P=0.026) and serum albumin (P\<0.001) and higher white blood cell (P\<0.001), blood urea nitrogen (P\<0.001), potassium (P=0.001), prothrombin time (P=0.027), INR (P=0.04), Child-Pugh score (P\<0.001), MELD score (P=0.023), recalibrated MELD score (P=0.023), and ALBI score (P\<0.001) than those admitted on regular hours. As for the interventions, patients admitted on off-hours had a higher proportion of blood transfusion (75.5% versus 59.5%, P\<0.001) and surgery (2.1% versus 0.3%, P=0.027) than those admitted on regular hours. As for the outcomes, patients admitted on off-hours had a higher 5-day rebleeding rate (16.5% versus 10.6%, P=0.038) and a larger amount of payment (¥29,361.51 versus ¥23,864.24, P\<0.001). In-hospital mortality and length of stay were not significantly different between the two groups (P=0.094 and P=0.856, respectively).

Among the patients without varices at endoscopy, no significant difference in demographics, etiology of liver disease, laboratory tests, Child-Pugh score, MELD score, recalibrated MELD score, ALBI score, and treatment options was observed between patients admitted on regular hours and off-hours (P\>0.05, in all comparisons). As for the outcomes, none died. Five-day rebleeding rate, length of stay, and total payment were not significantly different between the two groups (P=0.117, P=0.869, and P=0.187, respectively).

### 3.1.4. Patients\' Characteristics after Propensity Score Matching {#sec3.1.4}

After a 1:1 propensity score matching analysis, a total of 226 patients with liver cirrhosis and AUGIB were included. Baseline patient characteristics are described in [Table 2](#tab2){ref-type="table"}. Median age was 54.51 years (range: 6.28 to 81.62). Among them, 144 (63.7%) patients were male. Major etiology of liver diseases included hepatitis B virus infection (n=58, 25.7%) and alcohol abuse (n=50, 22. 1%). A majority of patients had Child-Pugh class B (n=121, 53.5%). Median MELD score at admission was 6.12 (-7.14 to 21.56). No, mild, moderate, and severe esophageal varices were observed in 11 (4.9%), 19 (4.4%), 23 (10.2%), and 182 (80.5%) patients, respectively. As for the treatment of AUGIB, 191 (84.5%) patients underwent endoscopic therapy, 8 (3.5%) patients underwent Sengstaken Blackmore tube placement, 218 (96.5%) patients received somatostatin and/or octreotide, 159 (70.4%) patients received blood transfusion, all patients received PPIs, and 1 (0.4%) patient underwent surgery. Five-day rebleeding rate was 14.2% (n=32). In-hospital mortality was 2.2% (n=5). Median length of hospital stay was 12.835 days (range: 2.76 to 78.00). Median total payment was ¥28,633.075 (range: 2,776.55 to 143,048.30).

### 3.1.5. Outcomes after Propensity Score Matching {#sec3.1.5}

After a 1:1 propensity score matching analysis, 113 patients were matched on each group ([Table 2](#tab2){ref-type="table"}). No significant difference in demographics, etiology of liver disease, laboratory tests, Child-Pugh score, MELD score, recalibrated MELD score, ALBI score, and treatment options was observed between the two groups (P\>0.05, in all comparisons). As for the outcomes, 5-day rebleeding rate, in-hospital mortality, length of stay, and total payment were not significantly different between the two groups (P=0.445, P=0.651, P=0.229, and P=0.390, respectively).

### 3.1.6. Subgroup Analyses after Propensity Score Matching {#sec3.1.6}

After a 1:1 propensity score matching analysis, 140 patients with endoscopically confirmed varices were matched on each group (Supplementary [Table 3](#supplementary-material-1){ref-type="supplementary-material"}). Patients admitted on off-hours had higher white blood cell (P=0.007), blood urea nitrogen (P=0.01), and potassium (P=0.001) than those admitted on regular hours. As for the interventions, patients admitted on off-hours had a higher proportion of blood transfusion (77.1% versus 58.6%, P=0.001) and surgery (2.9% versus 0%, P=0.044) than those admitted on regular hours. As for the outcomes, 5-day rebleeding rate, in-hospital mortality, length of stay, and total payment were not significantly different between the two groups (P=0.306, P=0.409, P=0.421, and P=0.058, respectively).

3.2. Validation Cohort {#sec3.2}
----------------------

### 3.2.1. Patients\' Characteristics {#sec3.2.1}

Between December 2014 and March 2018, a total of 173 patients with liver cirrhosis and AUGIB were included. Baseline patient characteristics are described in [Table 3](#tab3){ref-type="table"}. Median age was 56.60 years (range: 20.57 to 88.73). Among them, 121 (69.9%) patients were male. Major etiology of liver diseases included hepatitis B virus infection (n=47, 27.2%) and alcohol abuse (n=55, 31.8%). A majority of patients had Child-Pugh class B (94/169, 55.6%). Median MELD score at admission was 7.22 (-3.16 to 23.19). One hundred and fifty-one patients underwent endoscopy. No, mild, moderate, and severe esophageal varices were observed in 9 (6.0%), 23 (15.2%), 26 (17.2%), and 93 (61.6%) patients, respectively. The origin of bleeding could be evaluated in 162 patients, of whom only 4 did not have esophageal and/or gastric varices. As for the treatment of AUGIB, 139 (80.3%) patients underwent endoscopic therapy, 1 (0.6%) patients underwent Sengstaken Blackmore tube placement, 160 (92.5%) patients received somatostatin and/or octreotide, 88 (50.9%) patients received blood transfusion, 173 (100%) patients received PPIs, and 0 (0%) patients underwent surgery. Information regarding 5-day rebleeding was unavailable in one patient. Five-day rebleeding rate was 7.6% (13/172). In-hospital mortality was 2.3% (4/173). Median length of hospital stay was 10.10 days (range: 0.12 to 32.94). Total payment was ¥24,328.31 (range: 3,427.24 to 98,215.78).

### 3.2.2. Outcomes {#sec3.2.2}

No significant difference in demographics, etiology of liver disease, laboratory tests, Child-Pugh score, MELD score, recalibrated MELD score, ALBI score, and treatment options was observed between the two groups (P\>0.05, in all comparisons). As for the outcomes, 5-day rebleeding rate, in-hospital mortality, length of stay, and total payment were not significantly different between the two groups (P=0.579, P=0.973, P=0.335, and P=0.166, respectively) ([Table 3](#tab3){ref-type="table"}).

### 3.2.3. Patients\' Characteristics after Propensity Score Matching {#sec3.2.3}

After a 1:1 propensity score matching analysis, a total of 40 patients with liver cirrhosis and AUGIB were included. Baseline patient characteristics are described in [Table 4](#tab4){ref-type="table"}. Median age was 56.86 years (range: 20.57 to 75.64). Among them, 28 (70%) patients were male. Major etiology of liver diseases included hepatitis B virus infection (n=9, 22.5%) and alcohol abuse (n=14, 35%). A majority of patients had Child-Pugh class B (n=22, 55%). Median MELD score at admission was 5.82 (range: -2.38 to 23.19). No, mild, moderate, and severe esophageal varices were observed in 2 (5%), 5 (12.5%), 6 (15%), and 27 (67.5%) patients, respectively. As for the treatment of AUGIB, 38 (95%) patients underwent endoscopic therapy, no patient underwent Sengstaken Blackmore tube placement, 39 (97.5%) patients received somatostatin and/or octreotide, 21 (52.5%) patients received blood transfusion, all patients received PPIs, and no patient underwent surgery. Five-day rebleeding rate was 12.5% (n=5). In-hospital mortality was 2.5% (n=1). Median length of hospital stay was 11.95 days (range: 5.73 to 31.06). Median total payment was ¥24,961.33 (range: 11,212.15 to 81,125.52).

### 3.2.4. Outcomes after Propensity Score Matching {#sec3.2.4}

After a 1:1 propensity score matching analysis, 20 patients were matched on each group ([Table 4](#tab4){ref-type="table"}). No significant difference in demographics, etiology of liver disease, laboratory tests, Child-Pugh score, MELD score, recalibrated MELD score, ALBI score, and treatment options was observed between the two groups (P\>0.05, in all comparisons). As for the outcomes, 5-day rebleeding rate, in-hospital mortality, length of stay, and total payment were not significantly different between the two groups (P=0.633, P=0.311, P=0.441, and P=0.829, respectively).

4. Discussion {#sec4}
=============

Traditionally, a worse outcome in patients with UGIB during the weekend was potentially attributed to lower staffing levels and relatively younger and inexperienced staff \[[@B11]\]. Indeed, both overall analyses and subgroup analyses of patients with endoscopically confirmed varices in the test cohort demonstrated a significantly higher 5-day rebleeding rate and a larger amount of payment in patients admitted on off-hours. This might be primarily due to worse liver dysfunction in patients admitted on off-hours, such as lower albumin and higher prothrombin time, INR, Child-Pugh score, and ALBI score. As the Child-Pugh score was matched, the propensity score matching analyses of both test and validation cohorts showed no significant effect of admission time on the rebleeding rate, in-hospital mortality, length of stay, and total payment of cirrhotic patients with AUGIB. These findings suggested that the weekend effect might not be an independent risk factor for worse outcomes of cirrhotic patients with AUGIB.

A meta-analysis \[[@B16]\] found that off-hours admission was not associated with a higher risk of rebleeding rate (OR=1.06, 95%CI=0.83-1.35, and P=0.66) and longer length of stay (WMD 0.06 day, 95%CI=-0.30 - -0.42, P=0.747). These previous findings were consistent with our results regarding 5-day rebleeding rate and length of stay. Notably, our study focused on the 5-day rebleeding rate after treatment during hospitalization. However, the interval of rebleeding was not specified in the meta-analysis. As we have known, the length of stay was usually associated with the severity of illness \[[@B24]\]. In addition, as well known, liver dysfunction as estimated by Child-Pugh score and MELD score were risk factors for mortality of cirrhotic patients with AUGIB \[[@B25]--[@B27]\].

Two of the published meta-analyses \[[@B16], [@B17]\] demonstrated a significant weekend effect on the mortality in patients with nonvariceal UGIB, but not those with variceal bleeding. This finding seemed to be consistent with our results regarding mortality. Notably, our study focused on the outcomes during hospitalization, but not those after discharge. The fact is readily understood that admission time mainly influenced the in-hospitalization outcomes but marginally influenced the outcomes after discharge. Indeed, a meta-analysis also suggested that off-hours admission negatively influenced in-hospital mortality (P=0.009), rather than 30-day mortality (P=0.116).

Our study has the following advantages. First, we refined the definitions of off-hours admission. Second, we included a test cohort and a validation cohort which can reduce the sampling bias to some extent. Third, we employed a propensity score matching analysis. Thus, the patient characteristics, especially Child-Pugh and MELD scores which are significantly associated with prognosis of liver cirrhosis, are comparable between the two groups. Our results become more stable. However, the major drawback of our study should be that not all patients undergo endoscopy to evaluate the source of bleeding. Additionally, the sample size is not adequate in the validation cohort. Finally, a potential selection bias could not be neglected due to the retrospective nature of this study.

In conclusion, off-hours admission might not be associated with outcomes in patients with liver cirrhosis and AUGIB. However, the geographical difference should not be neglected to extrapolate our findings.

This study was partially supported by the grant from the Fourth Batch of Science and Technology Planning Projects of Liaoning Province in 2015 (no. 2015225019) for Professor Xiaozhong Guo.
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:   Acute upper gastrointestinal bleeding
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Supplementary Table 1. Treatment of cirrhotic patients with AUGIB at different departments from our hospital in test cohort. Supplementary Table 2. Subgroup analyses of patients with liver cirrhosis and AUGIB based on the origin of bleeding in test cohort. Supplementary Table 3. AUGIB patients with endoscopically confirmed varices after propensity matching analysis in test cohort.

###### 

Click here for additional data file.

###### 

Characteristics of patients with liver cirrhosis and AUGIB in test cohort.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Variables**                                  **No. Pts**   **Overall**                       **No. Pts**   **Regular hours**                 **No. Pts**   **Off-hours**                     **P value**
  ---------------------------------------------- ------------- --------------------------------- ------------- --------------------------------- ------------- --------------------------------- -------------
  Age (years)                                    826           55.27 (6.28-95.13)                486           54.54 (20.88-95.13)               340           55.95 (6.28-84.56)                0.074

  Sex (male)                                     826           564 (68.3%)                       486           337 (69.3%)                       340           227 (66.8%)                       0.434

  Etiology of Liver Diseases                     826                                             486                                             340                                             0.387

   HBV                                                         208 (25.2%)                                     126 (25.9%)                                     82 (24.1%)                         

   HCV                                                         51 (6.2%)                                       32 (6.6%)                                       19 (5.6%)                          

   HBV + HCV                                                   6 (0.7%)                                        2 (0.4%)                                        4 (1.2%)                           

   Alcohol Abuse                                               219 (26.5%)                                     125 (25.7%)                                     94 (27.7%)                         

   HBV + Alcohol Abuse                                         64 (7.7%)                                       42 (8.6%)                                       22 (6.5%)                          

   HCV + Alcohol Abuse                                         13 (1.6%)                                       7 (1.4%)                                        6 (1.8%)                           

   HBV + HCV + Alcohol Abuse                                   2 (0.2%)                                        1 (0.2%)                                        1 (0.3%)                           

   Drug Related                                                35 (4.2%)                                       23 (4.7%)                                       12 (3.5%)                          

   Autoimmune Liver Diseases                                   56 (6.8%)                                       26 (5.4%)                                       30 (8.8%)                          

   Other or Unclear Etiology                                   172 (20.8%)                                     102 (21%)                                       70 (20.6%)                         

  Laboratory Tests                                                                                                                                                                                

   Red Blood Cell (10^12^/L)                     822           2.56 (0.93-5.49)                  482           2.61 (0.93-5.49)                  340           2.49 (1.05-5.10)                  0.250

   Hemoglobin (g/L)                              822           72.00 (23.00-180.00)              482           73.00 (23.00-164.00)              340           71.00 (23.00-180.00)              0.512

   White Blood Cell (10^9^/L)                    822           4.70 (0.40-46.10)                 482           4.20 (0.80-33.50)                 340           5.30 (0.90-46.10)                 \<0.001

   Platelet Count (10^9^/L)                      822           75.00 (9.00-842.00)               482           74.00 (9.00-842.00)               340           77.50 (17.00-775.00)              0.429

   Total Bilirubin (umol/L)                      820           20.30 (3.30-679.10)               480           20.10 (4.10-679.10)               340           20.50 (3.30-250.80)               0.598

   Direct Bilirubin (umol/L)                     820           8.30 (0.50-413.80)                480           8.20 (1.30-413.80)                340           8.50 (0.50-195.20)                0.916

   Indirect Bilirubin (umol/L)                   820           11.75 (1.30-265.30)               480           11.50 (1.30-265.30)               340           12.05 (2.00-126.60)               0.436

   Albumin (g/L)                                 796           30.40 (9.60-49.30)                469           31.00 (9.60-49.30)                327           29.30 (10.00-48.00)               \<0.001

   Alanine Aminotransferase (U/L)                818           23.00 (5.00-1064.00)              479           23.00 (5.00-730.00)               339           24.00 (5.00-1064.00)              0.403

   Aspartate Aminotransferase (U/L)              818           31.00 (7.00-1487.00)              479           31.00 (7.00-1399.00)              339           32.00 (8.00-1487.00)              0.255

   Alkaline Phosphatase (U/L)                    818           73.00 (1.30-889.00)               479           74.00 (17.44-889.00)              339           72.00 (1.30-688.00)               0.535

   Gamma-glutamyl Transpeptidase (U/L)           818           35.00 (5.00-1168.00)              479           35.00 (5.00-1168.00)              339           37.00 (6.00-755.00)               0.945

   Blood Urea Nitrogen (mmol/L)                  792           7.71 (1.58-42.83)                 465           7.06 (1.58-42.83)                 327           8.21 (1.96-37.67)                 \<0.001

   Serum Creatinine (umol/L)                     791           61.00 (20.00-919.00)              465           60.00 (20.00-919.00)              326           61.00 (24.00-327.00)              0.284

   Potassium (mmol/L)                            810           4.06 (2.13-7.87)                  473           4.00 (2.13-7.07)                  337           4.12 (2.79-7.78)                  \<0.001

   Sodium (mmol/L)                               810           138.80 (83.00-160.80)             473           139.10 (83.00-160.80)             337           138.50 (116.40-152.40)            0.055

   PT (seconds)                                  794           16.20 (10.80-62.80)               465           15.90 (10.80-62.80)               329           16.50 (11.00-49.50)               0.034

   APTT (seconds)                                791           40.30 (25.70-180.00)              463           40.50 (25.7-180.00)               328           39.95 (27.30-97.20)               0.452

   INR                                           791           1.31 (0.77-7.96)                  463           1.28 (0.77-7.96)                  328           1.35 (0.79-5.94)                  0.040

  Child-Pugh Score                               776           7.00 (5.00-15.00)                 455           7.00 (5.00-15.00)                 321           7.00 (5.00-15.00)                 0.006

  Child-Pugh A/B/C                               776           234 (30.2%)/339  \                455           160 (35.2%)/216  \                321           74 (23.1%)/183  \                 0.001
                                                               (51.4%)/143 (18.4%)                             (47.5%)/79 (17.3%)                              (57.0%)/64 (19.9%)                

  MELD Score                                     772           6.37 (-7.52-38.22)                453           5.87 (-7.52-38.22)                319           7.06 (-7.44-37.65)                0.067

  Recalibrated MELD Score                        772           -4.00 (-6.87-2.60)                453           -4.10 (-6.87-2.60)                319           -3.85 (-6.85-2.48)                0.067

  ALBI Score                                     793           -1.70 (-3.31-0.22)                467           -1.77 (-3.31-0.03)                326           -1.59 (-3.13-0.22)                \<0.001

  Esophageal Varices (No/Mild/Moderate/Severe)   522           32 (6.1%)/24 (4.6%)/  \           309           20 (6.5%)/17 (5.5%)/  \           213           12 (5.6%)/7 (3.3%)/  \            0.650
                                                               54 (10.3%)/412 (78.9%)                          32(10.4%)/240 (77.6%)                           22 (10.3%)/172 (80.8%)            

  Treatment                                                                                                                                                                                       

   Endoscopic Treatment                          826           508 (61.5%)                       486           310 (63.8%)                       340           198 (58.2%)                       0.107

   Sengstaken Blakemore                          826           20 (2.4%)                         486           12 (2.5%)                         340           8 (2.4%)                          0.915

   Somatostatin and/or Octreotide                826           750 (90.8%)                       486           435 (80.5%)                       340           315 (92.7%)                       0.124

   Blood Transfusion                             826           544 (65.9%)                       486           295 (60.7%)                       340           249 (73.3%)                       \<0.001

   PPIs                                          826           813 (98.4%)                       486           477 (98.2%)                       340           336 (98.8%)                       0.443

   Surgery                                       826           8 (1.0%)                          486           2 (0.4%)                          340           6 (1.8%)                          0.051

  5-day Re-bleeding After Treatment              822           115 (14.0%)                       485           52 (10.7%)                        337           63 (18.7%)                        0.001

  Death During Hospitalization                   826           47 (5.7%)                         486           25 (5.1%)                         340           22(6.5%)                          0.418

  Length of Stay (days)                          826           11.23 (0.06-100.55)               486           11.27 (0.06-78.00)                340           11.13 (0.09-100.55)               0.830

  Total Payment (¥)                              826           23,120.87 (1,287.54-226,872.93)   486           22,017.42 (1,683.37-126,413.58)   340           25,906.83 (1,287.54-226,872.93)   \<0.001
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are expressed as median (range) or frequency (percentage).

*Abbreviations.* AUGIB: acute upper gastrointestinal bleeding; HBV: Hepatitis B virus; HCV: Hepatitis C virus; PT: prothrombin time; APTT: activated partial thromboplastin time; INR: international normalized ratio; MELD: model for end-stage liver disease; ALBI: albumin-bilirubin; PPIs: proton pump inhibitors; ¥: Renminbi.

###### 

Characteristics of patients with liver cirrhosis and AUGIB after propensity matching in test cohort.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Variables**                                                              **Propensity matching patients**                                      **P value**
  -------------------------------------- ----------------------------------- ---------------------------------- ---------------------------------- -------------
  Age (years)                            54.51 (6.28-81.62)                  54.41 (29.85-81.62)                54.60 (6.28-78.66)                 0.829

  Sex (male)                             144 (63.7%)                         73 (64.6%)                         71 (62.8%)                         0.782

  Etiology of Liver Diseases                                                                                                                       0.612

   HBV                                   58 (25.7%)                          29 (25.7%)                         29 (25.7%)                          

   HCV                                   14 (6.2%)                           7 (6.2%)                           7 (6.2%)                            

   HBV+ HCV                              1 (0.4%)                            1 (0.9%)                           0 (0%)                              

   Alcohol Abuse                         50 (22.1%)                          26 (23.0%)                         24 (21.2%)                          

   HBV+ Alcohol Abuse                    26 (11.5%)                          15 (13.3%)                         11 (9.7%)                           

   HCV+ Alcohol Abuse                    3 (1.3%)                            0 (0%)                             3 (2.7%)                            

   HBV+ HCV+ Alcohol Abuse               1 (0.4%)                            0 (0%)                             1 (0.9%)                            

   Drug Related                          10 (4.4%)                           5 (4.4%)                           5 (4.4%)                            

   Autoimmune Liver Diseases             12 (5.3%)                           5 (4.4%)                           7 (6.2%)                            

   Other or Unclear Etiology             51 (22.6%)                          25 (22.1%)                         26 (23.0%)                          

  Laboratory Tests                                                                                                                                  

   Red Blood Cell (10^12^/L)             2.54 (0.98-5.49)                    2.60 (0.98-5.49)                   2.53 (1.15-4.68)                   0.989

   Hemoglobin (g/L)                      71.50 (23.00-157.00)                72.00 (23.00-157.00)               71.00 (23.00-133.00)               0.901

   White Blood Cell (10^9^/L)            4.30 (1.00-26.30)                   4.10 (1.10-26.30)                  4.40 (1.00-17.50)                  0.239

   Platelet Count (10^9^/L)              74.00 (17.00-435.00)                72.00 (27.00-303.00)               79.00 (17.00-435.00)               0.538

   Total Bilirubin (umol/L)              18.80 (3.30-187.40)                 19.00 (6.10-90.40)                 18.40 (3.30-187.40)                0.669

   Direct Bilirubin (umol/L)             7.50 (0.50-151.60)                  7.50 (1.30-56.30)                  7.20 (0.50-151.60)                 0.384

   Indirect Bilirubin (umol/L)           11.35 (2.40-56.80)                  11.20 (3.20-41.10)                 11.40 (2.40-56.80)                 0.771

   Albumin (g/L)                         30.10 (10.00-49.30)                 30.48 (10.50-49.30)                29.40 (10.00-45.60)                0.580

   Alanine Aminotransferase (U/L)        23.00 (5.00-234.00)                 23.00 (6.00-234.00)                23.00 (5.00-154.00)                0.896

   Aspartate Aminotransferase (U/L)      31.00 (9.00-263.00)                 31.00 (12.00-263.00)               31.00 (9.00-175.00)                0.872

   Alkaline Phosphatase (U/L)            74.00 (17.44-707.00)                77.00 (17.44-707.00)               71.00 (21.00-685.00)               0.282

   Gamma-glutamyl Transpeptidase (U/L)   36.00 (8.00-1168.00)                45.00 (8.00-1168.00)               33.00 (9.00-737.00)                0.354

   Blood Urea Nitrogen (mmol/L)          7.62 (1.96-34.00)                   7.66 (2.04-34.00)                  7.61 (1.96-28.10)                  0.989

   Serum Creatinine (umol/L)             60.00 (28.00-234.00)                60.00 (28.00-225.70)               59.00 (30.50-234.00)               0.655

   Potassium (mmol/L)                    4.06 (2.90-5.50)                    4.05 (3.00-5.50)                   4.08 (2.90-5.50)                   0.285

   Sodium (mmol/L)                       138.50 (128.00-150.00)              138.30 (130.40-148.00)             138.50 (128.00-150.00)             0.773

   PT (seconds)                          15.80 (11.00-46.30)                 15.60 (12.10-36.10)                16.00 (11.00-46.30)                0.912

   APTT (seconds)                        39.55 (27.30-66.80)                 40.10 (28.20-66.80)                38.50 (27.30-63.90)                0.253

   INR                                   1.28 (0.79-4.77)                    1.26 (0.90-3.57)                   1.29 (0.79-4.77)                   0.950

  Child-Pugh Score                       7.00 (5.00-13.00)                   7.00 (5.00-12.00)                  7.00 (5.00-13.00)                  0.891

  Child-Pugh A/B/C                       72 (31.9%)/121 (53.5%)/33 (14.6%)   35 (31.0%)/64 (56.6%)/14 (12.4%)   37 (32.7%)/57 (50.5%)/19 (16.8%)   0.544

  MELD Score                             6.12 (-7.14-21.56)                  6.12 (-5.03-20.16)                 5.68 (-7.14-21.56)                 0.733

  Recalibrated MELD Score                -4.05 (-6.79 - -0.85)               -4.04 (-6.35 - -1.14)              -4.14 (-6.79 - -0.85)              0.733

  ALBI Score                             -1.70 (-3.23-0.22)                  -1.70 (-3.23 - -0.43)              -1.69 (-3.06-0.22)                 0.767

  Esophageal Varices  \                  11 (4.9%)/10 (4.4%)/23  \           5 (4.4%)/5 (4.4%)/11  \            6 (5.3%)/5 (4.4%)/12  \            0.984
  (No/Mild/Moderate/Severe)              (10.2%)/182 (80.5%)                 (9.8%)/92 (81.4%)                  (10.6%)/90 (79.7%)                 

  Treatment                                                                                                                                         

   Endoscopic Treatment                  191 (84.5%)                         96 (85.0%)                         95 (84.1%)                         0.854

   Sengstaken Blakemore                  8 (3.5%)                            5 (4.4%)                           3 (2.7%)                           0.472

   Somatostatin and/or Octreotide        218 (96.5%)                         107 (94.7%)                        111 (98.2%)                        0.150

   Blood Transfusion                     159 (70.4%)                         80 (70.8%)                         79 (69.9%)                         0.884

   PPIs                                  226 (100%)                          113 (100%)                         113 (100%)                         NA

   Surgery                               1 (0.4%)                            1 (0.9%)                           0 (0%)                             0.316

  5-day Re-bleeding After Treatment      32 (14.2%)                          14 (12.4%)                         18 (15.9%)                         0.445

  Death During Hospitalization           5 (2.2%)                            2 (1.8%)                           3 (2.7%)                           0.651

  Length of Stay (days)                  12.835 (2.76-78.00)                 12.97 (3.91-78.00)                 12.41 (2.76-45.26)                 0.229

  Total Payment (¥)                      28,633.075 (2,776.55-143,048.30)    26,733.81 (2,776.55-115,201.67)    29,361.51 (5,856.09-143,048.30)    0.390
  --------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are expressed as median (range) or frequency (percentage).

*Abbreviations*. AUGIB: acute upper gastrointestinal bleeding; HBV: Hepatitis B virus; HCV: Hepatitis C virus; PT, prothrombin time; APTT: activated partial thromboplastin time; INR: international normalized ratio; MELD: model for end-stage liver disease; ALBI: albumin-bilirubin; PPIs: Proton pump inhibitors; ¥, Renminbi.

###### 

Characteristics of patients with liver cirrhosis and AUGIB in validation cohort.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Variables**                                  **No. Pts**   **Overall**                                 **No. Pts**   **Regular hours**                          **No. Pts**   **Off-hours**                    **P value**
  ---------------------------------------------- ------------- ------------------------------------------- ------------- ------------------------------------------ ------------- -------------------------------- -------------
  Age (years)                                    173           56.60 (20.57-88.73)                         131           56.60 (20.57-75.73)                        42            56.56 (33.42-88.73)              0.683

  Sex (male)                                     173           121 (69.9%)                                 131           91 (69.5%)                                 42            30 (71.4%)                       0.809

  Etiology of Liver Diseases                     173                                                       131                                                      42                                             0.830

   HBV                                                         47 (27.2%)                                                37 (28.2%)                                               10 (23.8%)                        

   HCV                                                         17 (9.8%)                                                 12 (9.2%)                                                5 (11.9%)                         

   Alcohol Abuse                                               55 (31.8%)                                                41 (31.3%)                                               14 (33.3%)                        

   HBV + Alcohol Abuse                                         3 (1.7%)                                                  2 (1.5%)                                                 1 (2.4%)                          

   HBV + HCV + Alcohol Abuse                                   1 (0.6%)                                                  1 (0.8%)                                                 0 (0%)                            

   Drug Related                                                1 (0.6%)                                                  1 (0.8%)                                                 0 (0%)                            

   Autoimmune Liver Diseases                                   3 (1.7%)                                                  3 (2.3%)                                                 0 (0%)                            

   Other or Unclear Etiology                                   46 (26.6%)                                                34 (25.9%)                                               12 (28.6%)                        

  Laboratory Tests                                                                                                                                                                                                  

   Red Blood Cell (10^12^/L)                     173           2.70 (1.32-5.11)                            131           2.70 (1.32-5.11)                           42            2.62 (1.56-4.14)                 0.372

   Hemoglobin (g/L)                              173           73.00 (31.00-156.00)                        131           73.00 (31.00-156.00)                       42            73.50 (38.00-130.00)             0.575

   White Blood Cell (10^9^/L)                    173           4.20 (1.00-23.10)                           131           4.10 (1.00-23.10)                          42            4.35 (1.70-14.90)                0.368

   Platelet Count (10^9^/L)                      173           71.00 (18.00-457.00)                        131           73.00 (18.00-377.00)                       42            68.50 (23.00-457.00)             0.980

   Total Bilirubin (umol/L)                      172           20.80 (5.20-210.00)                         131           21.60 (5.20-210.00)                        41            18.30 (6.70-106.10)              0.587

   Direct Bilirubin (umol/L)                     172           8.70 (2.00-146.90)                          131           9.00 (2.00-146.90)                         41            8.30 (2.50-60.10)                0.643

   Indirect Bilirubin (umol/L)                   172           10.65 (2.60-79.90)                          131           11.40 (2.60-69.20)                         41            9.80 (4.20-79.90)                0.801

   Albumin (g/L)                                 171           29.40 (17.00-50.70)                         130           29.65 (17.20-50.70)                        41            29.40 (17.00-41.00)              0.693

   Alanine Aminotransferase (U/L)                172           20.70 (5.00-275.36)                         131           20.98 (6.00-140.00)                        41            17.17 (5.00-275.36)              0.504

   Aspartate Aminotransferase (U/L)              172           27.00 (9.63-310.39)                         131           27.50 (9.63-278.00)                        41            26.11 (10.00-310.39)             0.801

   Alkaline Phosphatase (U/L)                    172           78.23 (24.02-378.66)                        131           75.66 (24.02-378.66)                       41            79.75 (46.24-197.00)             0.981

   Gamma-glutamyl Transpeptidase (U/L)           172           31.98 (7.54-1227.00)                        131           29.61 (7.54-1227.00)                       41            40.53 (7.69-295.00)              0.346

   Blood Urea Nitrogen (mmol/L)                  172           7.60 (2.17-47.25)                           131           7.40 (2.17-47.25)                          41            7.96 (2.47-20.15)                0.993

   Serum Creatinine (umol/L)                     172           69.145 (34.40-267.63)                       131           67.03 (34.40-267.63)                       41            74.21 (34.90-144.98)             0.116

   Potassium (mmol/L)                            173           3.95 (2.48-5.54)                            131           3.95 (2.48-5.54)                           42            3.97 (3.12-5.49)                 0.876

   Sodium (mmol/L)                               173           138.50 (124.00-152.90)                      131           138.40 (130.40-152.90)                     42            138.80 (124.00-145.70)           0.544

   PT (seconds)                                  171           16.10 (10.50-27.40)                         131           16.10 (11.60-27.40)                        40            16.05 (10.50-27.20)              0.606

   APTT (seconds)                                170           37.85 (19.40-59.70)                         131           37.90 (27.50-59.70)                        39            37.40 (19.40-52.10)              0.542

   INR                                           170           1.32 (0.91-2.55)                            131           1.33 (1.01-2.55)                           39            1.31 (0.91-2.50)                 0.681

  Child-Pugh Score                               169           8.00 (5.00-15.00)                           130           8.00 (5.00-12.00)                          39            7.00 (5.00-12.00)                0.603

  Child-Pugh A/B/C                               169           51 (30.2%)/94 (55.6%)  \                    130           37 (28.5%)/75 (57.7%)  \                   39            14 (35.9%)/19 (48.7%)  \         0.596
                                                               /24 (14.2%)                                               /18 (13.8%)                                              /6 (15.4%)                       

  MELD Score                                     170           7.22 (-3.16-23.19)                          131           7.26 (-3.16-20.70)                         39            7.22 (-2.38-23.19)               0.671

  Recalibrated MELD Score                        170           -3.82 (-5.97- -0.51)                        131           -3.81 (-5.97- -1.03)                       39            -3.82 (-5.80- -0.51)             0.671

  ALBI Score                                     171           -1.63 (-3.40- -0.11)                        130           -1.62 (-3.40- -0.11)                       41            -1.68 (-2.70- -0.49)             0.675

  Esophageal Varices (No/Mild/Moderate/Severe)   151           9 (6.0%)/23 (15.2%)/26 (17.2%)/93 (61.6%)   116           6 (5.2%)/18 (15.5%)/20 (17.2)/72 (61.1%)   35            3 (8.6%)/5 (14.3%)/6  \          0.965
                                                                                                                                                                                  (17.1%)/21 (60.0%)               

  Treatment                                                                                                                                                                                                         

   Endoscopic Treatment                          173           139 (80.3%)                                 131           104 (79.4%)                                42            35 (83.3%)                       0.576

   Sengstaken Blakemore                          173           1 (0.6%)                                    131           0 (0%)                                     42            1 (2.4%)                         0.077

   Somatostatin and/or Octreotide                173           160 (92.5%)                                 131           119 (90.8%)                                42            41 (97.6%)                       0.147

   Blood Transfusion                             173           88 (50.9%)                                  131           62 (47.3%)                                 42            26 (61.9%)                       0.100

   PPIs                                          173           173 (100%)                                  131           131 (100%)                                 42            42 (100%)                        NA

   Surgery                                       173           0 (0%)                                      131           0 (0%)                                     42            0 (0%)                           NA

  5-day Re-bleeding After Treatment              172           13 (7.6%)                                   130           9 (6.9%)                                   42            4 (9.5%)                         0.579

  Death During Hospitalization                   173           4 (2.3%)                                    131           3 (2.3%)                                   42            1 (2.4%)                         0.973

  Length of Stay (days)                          173           10.10 (0.12-32.94)                          131           10.10 (0.12-32.94)                         42            10.28 (5.02-31.06)               0.335

  Total Payment (¥)                              173           24,328.31 (3,427.24-98,215.78)              131           22,685.20 (3,427.24-98,215.78)             42            25,213.81 (9,970.37-81,125.52)   0.166
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data are expressed as median (range) or frequency (percentage).

*Abbreviations*. AUGIB: acute upper gastrointestinal bleeding; HBV: Hepatitis B virus; HCV: Hepatitis C virus; PT: prothrombin time; APTT: activated partial thromboplastin time; INR: international normalized ratio; MELD: model for end-stage liver disease; ALBI: albumin-bilirubin; PPIs: proton pump inhibitors; ¥: Renminbi.

###### 

Characteristics of patients with liver cirrhosis and AUGIB after propensity matching in validation cohort.

  **Variables**                                                                        **Propensity matching patients**                                     **P value**
  ---------------------------------------------- ------------------------------------- ---------------------------------- --------------------------------- -------------
  Age (years)                                    56.86 (20.57-75.64)                   60.64 (20.57-75.64)                55.52 (35.18-74.33)               0.160
  Sex (male)                                     28 (70%)                              13 (65%)                           15 (75%)                          0.490
  Etiology of Liver Diseases                                                                                                                                0.622
   HBV                                           9 (22.5%)                             4 (20%)                            5 (25%)                            
   HCV                                           4 (10%)                               2 (10%)                            2 (10%)                            
   Alcohol Abuse                                 14 (35%)                              7 (35%)                            7 (35%)                            
   Drug Related                                  2 (5%)                                0 (0%)                             2 (10%)                            
   Autoimmune Liver Diseases                     1 (2.5%)                              1 (5%)                             0 (0%)                             
   Other or Unclear Etiology                     10 (25%)                              6 (30%)                            4 (20%)                            
  Laboratory Tests                                                                                                                                           
   Red Blood Cell (10^12^/L)                     2.625 (1.65-3.89)                     2.58 (1.69-3.89)                   2.705 (1.65-3.78)                 0.968
   Hemoglobin (g/L)                              74.50 (38.00-126.00)                  77.00 (53.00-122.00)               72.50 (38.00-126.00)              0.473
   White Blood Cell (10^9^/L)                    4.40 (1.80-14.90)                     4.40 (2.20-11.70)                  4.35 (1.80-14.90)                 0.839
   Platelet Count (10^9^/L)                      72.50 (27.00-301.00)                  72.50 (27.00-301.00)               72.00 (32.00-145.00)              0.978
   Total Bilirubin (umol/L)                      18.10 (5.50-106.10)                   16.85 (5.50-50.90)                 18.10 (8.50-106.10)               0.256
   Direct Bilirubin (umol/L)                     7.85 (2.20-60.10)                     7.10 (2.20-41.50)                  7.95 (3.00-60.10)                 0.675
   Indirect Bilirubin (umol/L)                   9.50 (2.80-46.00)                     8.55 (2.80-22.10)                  10.00 (5.40-46.00)                0.148
   Albumin (g/L)                                 30.65 (18.00-39.20)                   30.85 (19.00-38.60)                30.00 (18.00-39.20)               1
   Alanine Aminotransferase (U/L)                21.805 (6.79-88.77)                   21.805 (9.44-72.47)                20.415 (6.79-88.77)               0.756
   Aspartate Aminotransferase (U/L)              25.635 (10.74-136.00)                 28.38 (11.00-88.79)                25.635 (10.74-136.00)             0.978
   Alkaline Phosphatase (U/L)                    80.10 (40.34-234.00)                  80.94 (40.34-234.00)               78.245 (46.24-149.45)             0.705
   Gamma-glutamyl Transpeptidase (U/L)           41.245 (7.69-295.00)                  40.48 (13.71-254.00)               42.765 (7.69-295.00)              0.935
   Blood Urea Nitrogen (mmol/L)                  7.395 (2.98-18.83)                    7.055 (2.98-18.83)                 8.40 (4.65-18.72)                 0.245
   Serum Creatinine (umol/L)                     70.11 (34.90-143.10)                  66.68 (42.60-95.20)                74.255 (34.90-143.10)             0.117
   Potassium (mmol/L)                            3.95 (3.10-4.66)                      3.88 (3.10-4.66)                   3.98 (3.27-4.59)                  0.330
   Sodium (mmol/L)                               139.10 (124.00-145.70)                138.50 (135.00-141.40)             139.45 (124.00-145.70)            0.279
   PT (seconds)                                  15.80 (13.30-24.50)                   15.40 (13.30-23.90)                16.05 (13.50-24.50)               0.417
   APTT (seconds)                                36.25 (30.80-47.50)                   35.90 (30.80-45.20)                37.15 (32.20-47.50)               0.351
   INR                                           1.275 (1.02-2.19)                     1.255 (1.08-2.08)                  1.31 (1.02-2.19)                  0.516
  Child-Pugh Score                               8.00 (5.00-12.00)                     8.00 (5.00-12.00)                  7.00 (5.00-12.00)                 0.836
  Child-Pugh A/B/C                               14 (35%)/22 (55%)/4 (10%)             7 (35%)/12 (60%)/1 (5%)            7 (35%)/10 (50%)/3 (15%)          0.544
  MELD Score                                     5.82 (-2.38-23.19)                    5.51 (-1.04-14.75)                 6.51 (-2.38-23.19)                0.245
  Recalibrated MELD Score                        -4.11 (-5.80- -0.51)                  -4.17 (-5.53- -2.26)               -3.96 (-5.80- -0.51)              0.245
  ALBI Score                                     -1.67 (-2.62- -0.49)                  -1.73 (-2.44- -0.49)               -1.67 (-2.62- -0.60)              0.787
  Esophageal Varices (No/Mild/Moderate/Severe)   2 (5%)/5 (12.5%)/6 (15%)/27 (67.5%)   1 (5%)/3 (15%)/3 (15%)/13 (65%)    1 (5%)/2 (10%)/3 (15%)/14 (70%)   0.971
  Treatment                                                                                                                                                  
   Endoscopic Treatment                          38 (95%)                              19 (95%)                           19 (95%)                          1
   Sengstaken Blakemore                          0 (0%)                                0(0%)                              0(0%)                             NA
   Somatostatin                                  39 (97.5%)                            20 (100%)                          19 (95%)                          0.311
   Blood Transfusion                             21 (52.5%)                            9 (45%)                            12 (60%)                          0.342
   PPIs                                          40 (100%)                             20 (100%)                          20 (100%)                         NA
   Surgery                                       0 (0%)                                0 (0%)                             0 (0%)                            NA
  5-day Re-bleeding After Treatment              5 (12.5%)                             2 (10%)                            3 (15%)                           0.633
  Death During Hospitalization                   1 (2.5%)                              0 (0%)                             1 (5%)                            0.311
  Length of Stay (days)                          11.95 (5.73-31.06)                    11.95 (5.73-21.95)                 11.28 (7.52-31.06)                0.441
  Total Payment (¥)                              24,961.33 (11,212.15-81,125.52)       25,985.45 (15,513.68-56,952.12)    24,961.33 (11,212.15-81,125.52)   0.829

Data are expressed as median (range) or frequency (percentage).

*Abbreviations*. AUGIB: acute upper gastrointestinal bleeding; HBV: Hepatitis B virus; HCV: Hepatitis C virus; PT: Prothrombin time; APTT: activated partial thromboplastin time; INR, International normalized ratio; MELD: model for end-stage liver disease; ALBI: albumin-bilirubin; PPIs: proton pump inhibitors; ¥: Renminbi.

[^1]: Guest Editor: Eduardo Garcia Vilela
